GeneDx Holdings Corp. WGS revenue by segment, product and geography
In its fiscal year ending 2025-12-31, GeneDx Holdings Corp. reported revenue across 2 business segments; the largest, Gene Dx, was $423M, 99.0% of the filed sum (+40.0% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Gene Dx$423M99.0%+40.0% yoy
- All Other Segments$4.45M1.0%+41.0% yoy
Members sum to the consolidated $428M for this period.
- Diagnostic Test$417Mshare n/a+37.9% yoy
- Diagnostic Test Third Party Insurance$345Mshare n/a+47.1% yoy
- Diagnostic Test Institutional Customers$70.1Mshare n/a+7.6% yoy
- Product And Service Other$10.9Mshare n/a+230.1% yoy
- Diagnostic Test Self Pay$1.36Mshare n/a-41.9% yoy
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- Gene Dx$101M99.3%+16.5% yoy
- All Other Segments$758K0.7%no prior
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.